Navigation Links
WBAL Radio Segment With Dr. Leigh Vinocur Addresses Hope for the Rosacea Sufferer
Date:3/13/2009

- Dr. Vinocur Reports on University of California Rosacea-Specific Study -

NAPA, Calif., March 13 /PRNewswire-FirstCall/ -- On March 9, 2009, Dr. Leigh Vinocur, medical expert from the University of Maryland School of Medicine, was featured on WBAL-AM 1090 in a segment on rosacea, a condition afflicting over 14 million Americans. Dr. Vinocur addressed current therapies while reporting on a new study conducted at the Department of Dermatology, University of California, Irvine, in which rosacea patients were treated with a new cosmeceutical, Pyratine XR(TM) (0.125% furfuryl tetrahydropyranyl adenine).

Rosacea is a chronic skin disorder characterized by dilated blood vessels on the face, redness, inflammation, and lesions (papules and pustules). According to Dr. Vinocur, traditional treatments for rosacea focus on topical and oral antibiotics for their anti-inflammatory properties, but the new study showed that cytokinins, natural plant-derived growth factors known for their antioxidant and moisture retention benefits, appear to significantly reduce rosacea symptoms.

Over the 48-week study with Pyratine XR(TM) there was an overall clinical improvement in 80% of subjects with a 90% improvement in lesions, 45% improvement in redness, and a 28% improvement in spider veins. The product also appeared to improve the skin barrier function with a 41% improvement in skin dryness as early as week four while appearing to concurrently reduce fine lines, wrinkles and hyperpigmentation.

Pyratine XR(TM) is manufactured by Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that target the science of healthy aging. Pyratine XR(TM) officially launched at the American Academy of Dermatology's 67th Annual Meeting in San Francisco, March 6-10, 2009.

For more information on Pyratine XR(TM), please visit www.PyratineXR.com.

About Senetek, PLC

Senetek PLC (OTCBB:SNKTY) is a life sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of kinetin, the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at www.senetekplc.com.


'/>"/>
SOURCE Senetek PLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CyberKnife Radiosurgery for Lung Cancer Sees Increased Interest and Continued Rapid Growth
2. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
3. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
4. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
5. Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
8. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
9. Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology
10. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
11. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):